S ystemic lupus erythematosus (SLE) and primary Sjögren's syndrome (pSS) are systemic autoimmune diseases that strongly associate with a hyperactivated type I IFN system. This manifests as the overexpression of hundreds of IFNstimulated genes (ISGs) in peripheral blood cells, the so-called IFN-signature, which positively correlates with disease activity (1) (2) (3) (4) (5) . SLE and pSS patients are also characterized by the presence of autoantibodies against intracellular Ags, indicating that the B cell selection in these patients is not functioning properly. BAFF is a cytokine that is important for the development and selection of B cells. Mice that lack BAFF have a dramatic reduction in the numbers of follicular and marginal zone B cells, whereas mice that overexpress BAFF develop symptoms of systemic autoimmunity because of escape of autoreactive clones and increased T cell help in germinal centers (6) . Interestingly, the levels of autoantibodies in pSS patients correlate with the levels of BAFF, suggesting that BAFF also plays an active role in human systemic autoimmune diseases (7) . Increased BAFF levels have been suggested to play a role in both SLE and pSS (8, 9) . Indeed, because of the increased BAFF levels in serum of SLE and pSS patients, biologics have been developed to block BAFF (10, 11) . BAFF blockade using a human anti-BAFF mAb (belimumab) is the first U.S. Food and Drug Administration-approved treatment of SLE using a biologic (12) ; in addition, promising phase II clinical trials are completed for belimumab in pSS (11) . Interestingly, BAFF expression is induced in vivo by type I IFNs, although the exact molecular mechanisms for this remain unknown (13, 14) . Understanding how the expression of BAFF is related to the activity of the type I IFN system in SLE and pSS might give important clues to the underlying mechanisms of these diseases. Two previous reports have analyzed the promoter of the BAFF gene and identified putative transcription factor binding sites (TFBS) in the proximal promoter region (15, 16) . Woo et al. (16) identified a putative IFN-stimulated response element (ISRE) site but failed to validate it by mutational analysis; furthermore, the reported ISRE site is not conserved between species, indicating that it is a nonfunctional site. Surprisingly, Moon et al. (15) did not identify any ISRE site in the promoter of BAFF. To clarify the mechanism for how type I IFNs may drive the expression of BAFF, we set out to verify that BAFF is directly induced by type I IFNs as a bona fide ISG and to identify genuine TFBS in the BAFF promoter. We first treated multiple sclerosis (MS) patients de novo with IFN-b (Avonex) and quantified the BAFF expression in sorted immune cell subsets before and after treatment. We also sorted immune cell subsets from pSS patients and healthy control subjects followed by quantification of BAFF expression in neutrophils, monocytes, and lymphocytes. BAFF was strongly induced in neutrophils after IFN-b treatment; in addition, BAFF expression correlated with the activity of the type I IFN system in neutrophils *Unit of Experimental Rheumatology, Department of Medicine, Center for Molecular Medicine, Karolinska Institutet, SE-171 76 Stockholm, Sweden; from pSS patients. To identify well-conserved TFBS in the promoter of BAFF, we used phylogenetic footprinting and identified a highly conserved ISRE site adjacent to the transcriptional start site (TSS) in the BAFF gene. By using luciferase reporter assays we could identify that IFN regulatory factor (IRF) 1 and IRF2 as potent activators of BAFF expression, and that specific mutations of the identified ISRE site completely abolished the induction of the BAFF by IRF1 and IRF2. Furthermore, we identified IRF4 and IRF8 as strong repressors of BAFF expression and as antagonists to IRF1. We have thus demonstrated that type I IFNs drive the expression of BAFF via the binding of IRFs to a novel ISRE site in the BAFF promoter. In summary, these results might contribute to understanding how BAFF is involved in type I IFN-associated systemic autoimmune diseases.
Materials and Methods

Patients
Blood samples were taken from eight treatment-naive MS patients (one male and seven female patients) before and 18 h after their first Avonex (IFN-b-1a) injection (30 mg/0.5 ml). Blood samples were taken from 21 autoantibody-positive pSS patients who were diagnosed according to the revised European-American consensus criteria. This study was approved by the Regional Ethical Ethics Committee, Stockholm, and all subjects gave informed, written consent.
Cell sorting
Blood samples were subjected to Ficoll-Hypaque (GE Healthcare) separation. First, the PBMC fraction was isolated according to the manufacturer's protocol; then the remaining gradient was removed without disturbing the granulocyte/erythrocyte pellet. Twenty-five milliliters PBS (Sigma-Aldrich) and 25 ml 3% dextran (VWR) solution was added and the tube was inverted 10 times before it was incubated for 18-20 min at room temperature. The upper, straw-colored fraction was then removed and centrifuged for 10 min at 1000 rpm. Remaining erythrocytes were lysed by adding distilled water for 1 min, followed by addition of PBS to restore isotonicity. PBMCs were stained with CD14-allophycocyanin-Cy7, CD3-FITC, and CD19-allophycocyanin, and neutrophils were stained with CD15-PE (all Abs were from BD Biosciences). During flow cytometry a live gate was applied and populations were detected based on their respective fluorophore. The cells were sorted using a MoFlo flow cytometry cell sorter (Becton Coulter). To isolate CD14 + monocytes for in vitro stimulation using a blocking anti-IFNAR2 Ab, we first isolated PBMCs using Ficoll-Hypaque as described earlier. We then used magnetically labeled anti-CD14 beads (Miltenyi) to isolate human monocytes.
Stimulation of human monocytes with plasma
We cultured human THP-1 monocytic leukemia cells and primary human CD14 + monocytes in 24-well plates (0.5 ml, 10 6 cells/well). Cells were stimulated in triplicates for 18 h with plasma taken from MS patients before and after Avonex treatment (50 ml plasma/well). To block type I IFN signaling, we pretreated cells with 5 mg/ml of a blocking anti-IFNAR2 Ab (clone MMHAR-2; PBL Assay Science) for 45 min before addition of plasma. Eighteen hours poststimulation the cells were collected and lysed in TRIzol (Life Technologies) for RNA isolation and gene expression analysis using TaqMan quantitative RT-PCR.
Gene expression analysis
TRIzol (Life Technologies) and chloroform (Sigma-Aldrich) were used to extract total RNA from cells sorted from peripheral blood of patients. A total of 50 mg glycogen (Life Technologies) was added during the extraction to enhance RNA yield. RNA quality and quantity were determined using Nano Drop ND-1000 spectrophotometer (Thermo Scientific). cDNA was synthesized using iScript cDNA Synthesis Kit (Bio-Rad) according to the manufacturer's protocol, and concentrations were within the range 3-10 ng/ml. Amplification was performed using TaqMan probes; MX1: Hs00895608, BAFF: Hs00198106, OAS2: Hs00942643_m1, ACTB: Hs01060665, HPRT: Hs01003267 (Applied Biosystems). Relative expression was calculated using the DCt method using HPRT or ACTB for normalization. Gene expression data for BAFF (TNFSF13B) in PBMCs of pSS patients and healthy control subjects were obtained from Gene Expression Omnibus (GSE48378) and analyzed using Multi Experiment Viewer (MeV) and GraphPad Prism software.
BAFF promoter analysis
Using phylogenetic footprinting (rVista 2.0 and ConSite), we searched for conserved TFBS in the 23 kg bp (kb) to +0.5 kb region of the human BAFF (TNFSF13B) gene. We identified a strongly conserved ISRE site adjacent to the TSS (+1) of BAFF. We cloned a 1-kb fragment of the BAFF gene (2867 to +150) and inserted it into the pGL4.14-luc2 plasmid to generate a BAFF reporter construct (BAFF-luc). To verify that the identified ISRE site was functional, we mutated two nucleotides in the ISRE site (mutated BAFF promoter [BAFF-mut]). We used X-tremeGENE 9 
, and then prepared for gene expression analysis. (B and C) Expression levels of MX1 and BAFF were quantified in the different cell populations before and after IFN-b treatment using quantitative RT-PCR. The expression levels were normalized to ACTB. Statistics were calculated using the Wilcoxon matched-pairs test (*p # 0.05, **p # 0.01).
(Roche) to transfect HEK293T cells in 24-well plates with these reporter constructs together with IRF constructs and pRL-TK-Renilla for normalization. Luminescence was measured 24 h posttransfection using the Modulus Single Tube Reader (Promega). Relative luminescence unit is reported as firefly (Photinus) luciferase signal divided by Renilla luciferase signal.
Plasmids
The IRF-encoding plasmids were generated as previously described (17) by inserting the coding cDNA of IRFs into the pFLAG-CMV-6c plasmid (Sigma) using TOPO-based PCR cloning. BAFF-luc was generated by PCR cloning of a 1-kb promoter region from the RP23-9206 bacterial artificial chromosome (BACPAC Resources Center, CHORI) that was inserted into pGL4.14-luc2 (Promega). The BAFF-mut was generated by gene synthesis (MWG Eurofins) and inserted into the pEX-K4 vector. The BAFF-mut sequence was amplified by PCR using AccuPrime Pfx DNA polymerase (Invitrogen) and inserted into the pGL4.14 plasmid (Promega) using BglII and XhoI (Thermo Scientific). All plasmids were verified by Sanger sequencing. Plasmid sequences are available on request.
Statistics
The GraphPad Prism software was used for statistical tests and for generating graphs. The analysis of expression data from before and after treatment with Avonex was performed using the Wilcoxon matched-pairs test. BAFF expression levels in pSS patients versus healthy control subjects were analyzed using Student t test. Pearson correlation was used to calculate the correlation between expression levels of BAFF and MX1. Expression data from cells treated with human plasma were analyzed using Student t test.
Results
BAFF production in neutrophils and monocytes is driven by type I IFN in vivo
To determine how type I IFNs influence BAFF expression in different immune cell subsets in humans, we sorted peripheral blood cells from treatment-naive MS patients before and after de novo treatment with IFN-b. Peripheral blood was collected before treatment and 18 h posttreatment. After Ficoll separation, T cells (CD3 + ), B cells (CD19 + ), and monocytes (CD14 + ) were sorted from the interphase, whereas neutrophils (CD15 + ) were sorted from the granulocyte fraction (Fig. 1A) . We first quantified the expression of the canonical ISG MX1 before and after Avonex treatment to verify that IFN-b triggered a response in patients and control subjects (Fig. 1B) . IFN-b treatment also triggered a strong induction of BAFF expression, primarily in neutrophils, demonstrating that BAFF is a typical ISG (Fig. 1C) . BAFF was also ) and neutrophils (CD15 + ) from pSS patients followed by gene expression analysis of BAFF and MX1. BAFF expression levels correlated with MX1 expression levels in monocytes (n = 19) and neutrophils (n = 21). Expression levels were normalized to HPRT. Pearson correlation test was used to calculate p and r values. (C) To determine BAFF expression in immune cells of pSS patients, we mined gene expression data from 11 pSS patients and 17 healthy control subjects (HC), and found that BAFF expression was higher in PBMCs from pSS patients. Student t test was used to calculate the p value. To verify that type I IFN is a direct inducer of BAFF in monocytes, we treated THP-1 cells (D and E) and primary human CD14 + monocytes (F and G) with plasma from Avonex-treated MS patients while blocking type I IFN signaling with an anti-IFNAR2 Ab (clone MMHAR-2). Plasma from patients before Avonex treatment (UT) did not induce expression of OAS2 or BAFF, whereas plasma from the same patients after Avonex treatment (18 h posttreatment) induced the expression of OAS2 and BAFF. Importantly, pretreating cells with an anti-IFNAR2 Ab completely abolished the induction of OAS2 and BAFF, demonstrating that type I IFN directly induces BAFF. One representative data from three experiments are shown (n = 3). Expression levels were normalized to ACTB, and statistics were calculated with Student t test (*p # 0.05, **p # 0.01).
induced in monocytes and in T cells. These data establish that IFN-b induces the expression of BAFF primarily in CD15 + neutrophils in vivo in humans.
BAFF expression is directly induced by type I IFN and positively correlates with the IFN-signature in pSS patients
It has previously been reported that BAFF levels are increased in serum from patients with SLE and pSS, and that BAFF levels correlate with the IFN-signature in monocytes from pSS patients (3, 7, 18, 19) . To address this in additional cell types, we used flow cytometry to sort CD3 + , CD19 + , CD14 + , and CD15 + cells from peripheral blood of patients with pSS and healthy control subjects, followed by gene expression analysis. The expression levels of BAFF in both monocytes and neutrophils positively correlated with expression levels of the type I IFN surrogate marker MX1 ( Fig. 2A, 2B) . The correlation between BAFF expression and activity of the type I IFN system was, however, strongest in neutrophils. We could also show that BAFF expression is increased in PBMCs from pSS patients compared with PBMCs from healthy control subjects, this by mining public expression data (GSE48378) (Fig. 2C) . Because IFN-b (Avonex) triggered BAFF expression in vivo, and BAFF levels positively correlated with MX1, we hypothesized that the production of BAFF is directly controlled by type I IFNs. To verify that IFN-b directly induces BAFF expression, we stimulated monocytes in vitro with plasma from Avonex-treated MS patients while blocking the IFNAR receptor using a blocking anti-IFNAR2 Ab (Fig. 2D-G) . Plasma from Avonex-treated MS patients induced expression of the ISG OAS2 and of BAFF in THP-1 monocytic leukemia cells (Fig. 2D-E ) and in primary human CD14 + monocytes (Fig. 2F, 2G ). In contrast, plasma from the same patients before Avonex treatment did not induce the expression of OAS2 and BAFF. Importantly, blocking the IFNAR receptor with an anti-IFNAR2 Ab completely abolished the induction of OAS2 and BAFF, demonstrating that type I IFN directly causes the induction of BAFF.
Identification of a novel ISRE site in the BAFF promoter
Because type I IFN directly induced BAFF expression in monocytes, and BAFF expression is positively correlated with the IFNsignature in pSS patients, we reasoned that type I IFN is likely to drive the expression of BAFF via JAK/STAT signaling. Earlier studies of the BAFF promoter have indeed reported g activated sites (GAS) and ISRE sites, but importantly these sites are not conserved and were not functionally validated by mutational analysis (15, 16) . This could be because sequence conservation of the identified TFBS was not considered or because updated position weight matrix-based prediction tools were not used for TFBS prediction. To clarify this, we first used position weight matrix-based phylogenetic footprinting tools (rVista 2.0 and ConSite) to identify conserved GAS or ISRE sites in the promoter of BAFF (Fig. 3A, 3C) . By comparing the genomic sequence of the proximal BAFF promoter between different species, we identified a highly conserved ISRE site adjacent to the TSS (Fig. 3B) . Importantly, this ISRE site was not identified by two previous studies on the BAFF promoter (15, 16) . In contrast with Woo et al. (16), we did not identify any conserved GAS site in the BAFF promoter (20) . This could be because Woo et al. (16) did not consider sequence conservation while predicting TFBS.
BAFF expression is controlled by IRFs
To verify the functionality of the identified ISRE site, we first generated a luciferase reporter construct (BAFF-luc) containing a 1000-bp fragment of the BAFF gene including the core promoter, the TSS, and the ISRE site (Fig. 4A) . Type I IFNs activate the transcription factors IRF1, IRF2, and IRF9 followed by their binding to ISRE sites. To identify IRFs that regulate the expression of BAFF, we performed BAFF-luc reporter assays after cotransfection with a panel of IRFs. Only IRF1 and IRF2 could potently activate the BAFF-luc reporter (Fig. 4B) . We also generated a BAFF-mut construct where the two core GAAA elements of the identified ISRE site were altered to AAAA (Fig. 4C) . Importantly, IRF1 and IRF2 failed to activate luciferase expression from the BAFF-mut construct, demonstrating the functionality of the identified ISRE site (Fig. 4D) . Previous reports have demonstrated that IRF4 and IRF8 are potent repressors of the expression of ISGs (17) , and to test whether this also applies to BAFF, we cotransfected the BAFF-luc construct with IRF1 together with IRF4 or IRF8. Indeed, both IRF4 and IRF8 were potent repressors of IRF1-dependent activation of the BAFF promoter (Fig. 4E) . Cotransfecting the BAFF-luc reporter together with IRF1 and IRF8 without DNA-binding domain, we demonstrated that the repressive effect of IRF8 is dependent on DNA binding (Fig. 4E) . Transfection with a pool of IRF3, IRF5, IRF7, and IRF9 did not affect the activity of the BAFF-luc reporter (Fig. 4F) . In summary, we have identified a novel functionally validated ISRE site in the promoter of BAFF that is regulated by several members of the IRF transcription factor family.
Discussion
BAFF levels are increased in serum of patients with pSS and SLE; however, the exact mechanism for this increase in BAFF is not known (7, 18, 19, 21) . Interestingly, several reports have linked BAFF expression to type I IFNs, and it has been reported that BAFF expression is increased in human immune cells and serum after IFN-b treatment (13, 14, 22, 23) . These reports, however, did not use flow cytometry to isolate highly pure cell populations and did not explicitly compare and report BAFF levels in isolated cells before and after IFN-b treatment. Also, these reports failed to identify and validate any regulatory elements in the BAFF promoter. To demonstrate that BAFF is a direct target gene of type I IFNs, and to identify genuine TFBS in the BAFF promoter, we first isolated highly pure cell subsets and directly compared BAFF expression before and after IFN-b treatment of humans. We also isolated pure immune cell subsets from pSS patients and healthy control subjects to compare BAFF expression. In this article, we demonstrate that BAFF is directly induced by type I IFN in vivo in humans, and that the level of BAFF expression in neutrophils from pSS patients is positively correlated to the activity of the type I IFN system. Furthermore, we demonstrate that the induction of BAFF expression is directly due to type I IFN signaling via the transcription factors IRF1 and IRF2. We identified an ISRE site adjacent to the TSS of the BAFF gene, and functionally validated this ISRE site by mutating the GAAAGTGAAA sequence into AAAAGTAAAA. Indeed, this mutation of the ISRE site completely abolished the induction of the BAFF reporter by IRF1 and IRF2. In addition, the expression of BAFF was blocked by the myeloid-and lymphoid-specific transcription factors IRF4 and IRF8. A mutant of IRF8, lacking the DNA-binding domain, was unable to repress IRF1, indicating that the repression of BAFF by IRF8 was mediated by direct competition for the ISRE site. The strong repression of BAFF mediated by IRF4 and IRF8 suggests that BAFF is tightly regulated by these two transcription factors; indeed, a previous report has identified IRF8 as a repressor of BAFF expression in B cells (24) . In summary, our data demonstrate that BAFF expression is directly downstream of type I IFN signaling, and that members of the IRF family tightly regulate the expression of BAFF. Because increased BAFF expression is caused by type I IFNs, it is likely that novel IFN blockers will lead to a reduction in type I IFN signaling and a concomitant reduction of BAFF levels as previously has been suggested (25) . Understanding the precise mechanisms whereby type I IFNs control BAFF expression might contribute to revealing the role of BAFF in systemic autoimmune diseases.
